EU nod for Bimzelx for moderate to severe plaque psoriasis
The European Commission (EC) has granted marketing authorisation for UCB’s Bimzelx (bimekizumab) for the treatment of moderate to severe plaque psoriasis in adults w...
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingExploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingExploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingHighlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement